MALE PATTERN BALDNESS: COLLABORATIVE APPROACHES TO PATIENT-CENTERED CARE
Faculty:
L. Austin Fredrickson, MD, FACP
L. Austin Fredrickson is an Associate Professor of Internal Medicine at Northeast Ohio Medical University, where he serves as core faculty and teaches diagnostics, therapeutics, clinical skills, and health humanities. He is board-certified in general internal medicine and practices rural primary care. 
Kristina (Tia) Neu, RN
Kristina (Tia) Neu is a licensed Registered Nurse and author currently developing in-service training for healthcare professionals. She is a National Board-Certified Health & Wellness and Lifestyle Medicine Coach. Her work experience includes several areas of the healthcare profession, such as psychiatric nursing, medical nursing, motivational health coaching, chronic case management, dental hygiene, cardiac technician, and surgical technician.
Liz Fredrickson, PharmD, BCPS
Liz Fredrickson, PharmD, BCPS, is an Associate Professor of Pharmacy Practice and Pharmaceutical Sciences at the Northeast Ohio Medical University (NEOMED) College of Pharmacy, where she is course director of the Parenteral Products and Basic Pharmaceutics Lab courses.
Pamela Sardo, PharmD, BS
Pamela Sardo, PharmD, BS, is a freelance medical writer and licensed pharmacist. She is the founder and principal at Sardo Solutions in Texas. Pam received her BS from the University of Connecticut and her PharmD from the University of Rhode Island. Pam’s career spans many years in retail, clinics, hospitals, long-term care, Veterans Affairs, and managed health care responsibilities across a broad range of therapeutic classes and disease states.
Abstract
Androgenetic alopecia (AGA), also known as male androgenetic alopecia (MAA) or male pattern baldness in men, is the most common form of hair loss in adult men. This chronic and progressive condition follows a characteristic pattern. While MAA is often dismissed as a cosmetic issue, it can lead to significant emotional distress, reduced self-esteem, and social stigma. The healthcare team needs to understand evidence-based treatment options to support patients in making informed decisions and receiving individualized care. This continuing education activity provides a comprehensive overview of the pathophysiology of male pattern baldness and current pharmacological treatment options, including over-the-counter (OTC) products. An emphasis will be placed on the collaborative roles of healthcare professionals in setting appropriate expectations, monitoring treatment, and supporting adherence through coordinated care.
Accreditation Statements
In support of improving patient care, RxCe.com LLC is jointly accredited by the Accreditation CouncilTM for Continuing Medical Education (ACCME®), the Accreditation Council for Pharmacy Education (ACPE®), and the American Nurses Credentialing Center (ANCC®), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 2 Interprofessional Continuing Education (IPCE) credits for learning and change.
Joint Universal Activity Number: The Joint Accreditation Universal Activity Numbers assigned to this activity are as follows:
Pharmacists: JA4008424-0000-26-033-H01-P
Pharmacy Technicians: JA4008424-0000-26-033-H01-T
Credits: 2 contact hour(s) (0.2 CEU(s)) of continuing education credit.
Credit Types:
IPCE Credits - 2 Credits
AAPA Category 1 Credit™️ - 2 Credits
AMA PRA Category 1 Credit™️ - 2 Credits
Pharmacy - 2 Credits
Type of Activity: Knowledge
Media: Computer-Based Training (i.e., online courses)
Estimated time to complete activity: 2 contact hour(s) (0.2 CEU(s)), including Activity Pre-Test, Post-Test, and Activity Evaluation.
Release Date: March 18, 2026 Expiration Date: March 18, 2029
Target Audience: This educational activity is for Physicians, Physician Assistants, Pharmacists, and Pharmacy Technicians
How to Earn Credit: From March 18, 2026, through March 18, 2029, participants must:
Read the “learning objectives” and “author and planning team disclosures;”
Take the “Educational Activity Pre-Test;”
Study the section entitled “Educational Activity;” and
Complete the Educational Activity Post-Test and Activity Evaluation. The Educational Activity Post-Test will be graded automatically. Following successful completion of the Educational Activity Post-Test with a score of 70% or higher, a statement of participation will be made available immediately. (No partial credit will be given.)
CME Credit: Credit for this course will be uploaded to CPE Monitor® for pharmacists. Physicians may receive AMA PRA Category 1 Credit™️ and use these credits toward Maintenance of Certification (MOC) requirements. Physician Assistants may earn AAPA Category 1 CME credit, reportable through PA Portfolio. All learners shall verify their individual licensing board’s specific requirements and eligibility criteria.
Statement of Need
Male pattern baldness (androgenic alopecia) is the most common form of hair loss in adult men. It affects over 50% of males by age 50 and causes psychosocial distress, diminished self-esteem, and reduced quality of life. The perception of male pattern baldness as a cosmetic issue, and gaps in recognizing its androgen-dependent pathophysiology and clinical presentation are evidenced by the underutilization of evidence-based treatment, and failure to address patient adherence or the emotional impact. Gaps remain in the approach to pathophysiology, clinical presentation, and treatment comparison. There is a lack of uniform understanding of the mechanism of action, treatment-related side effects, and optimal methods for counseling patients. This activity aims to address these practice gaps to improve interprofessional management and outcomes.
Learning Objectives: Upon completion of this educational activity, participants should be able to:
Explain the pathophysiology and common clinical presentation of male pattern baldness
Compare and Contrast pharmacologic treatments for male pattern baldness, including mechanisms of action and safety profiles
Counsel patients on realistic treatment expectations, adverse effects
Identify the roles of healthcare team members in the management of male pattern baldness
Disclosures
The following individuals were involved in developing this activity: L. Austin Fredrickson, MD, FACP; Liz Fredrickson, PharmD, BCPS; Kristina (Tia) Neu, RN; and Pamela Sardo, PharmD, BS. None of the individuals involved in developing this activity has a conflict of interest or financial relationships related to the subject matter. There are no financial relationships or commercial or financial support relevant to this activity to report or disclose by RxCe.com or any of the individuals involved in the development of this activity.
© RxCe.com LLC 2026: All rights reserved. No reproduction of all or part of any content herein is allowed without the prior, written permission of RxCe.com LLC.
Educational Activity Pre-Test
Which of the following is the only FDA-approved over-the-counter pharmacologic treatment for male pattern baldness?
Finasteride
Dutasteride
Minoxidil
Ketoconazole
What is a common early effect of minoxidil use that patients should be counseled about?
Severe hypotension
Increased hair shedding in the first few weeks of treatment
Sudden skin hyperpigmentation
Scalp infections
Which of the following is most accurate regarding combination therapy with minoxidil and finasteride?
Combination leads to slower results than monotherapy
Combination is contraindicated in patients with hypertension
Combination is more effective than either agent alone
Combination has not been studied in clinical trials
Educational Activity
Male Pattern Baldness: Collaborative Approaches to Patient-Centered Care
Introduction
Male pattern baldness is the most common form of hair loss in adult men. This continuing education activity provides a comprehensive overview of the pathophysiology of male pattern baldness and current pharmacological treatment options, including over-the-counter (OTC) products. An emphasis will be placed on the collaborative roles of healthcare professionals in setting appropriate expectations, monitoring treatment, and supporting adherence through coordinated care.
Androgenetic alopecia (AGA), also known as male androgenetic alopecia (MAA) or male pattern baldness, is the most common form of hair loss in adult men, accounting for over 95% of cases.1 This chronic and progressive condition follows a characteristic pattern—typically beginning with bitemporal recession and thinning at the vertex—and affects more than half of all men by the age of 50.1 Despite being medically benign, MAA can have a profound psychosocial impact, often leading to diminished self-esteem, reduced confidence, and a lower quality of life, regardless of the degree of hair loss.1
Androgenetic alopecia is characterized by the gradual, nonscarring miniaturization of hair follicles and a shortened anagen phase in genetically predisposed individuals. In men, this process leads to the transformation of thick terminal hairs into fine vellus-like hairs, with distribution classified by the Hamilton-Norwood scale. Androgenetic alopecia is an androgen-dependent condition with a polygenic pattern of inheritance and variable expression.2 Balding typically begins in the late teens or early twenties and progresses in a predictable fashion, often sparing the occipital and lateral scalp.2
While MAA is often dismissed as a cosmetic issue, it can lead to significant emotional distress, reduced self-esteem, and social stigma. It is vital for the healthcare team to understand evidence-based treatment options to help patients make informed decisions and receive individualized care.
Patient Case
MR is a 42-year-old male high school teacher who presents with gradual hair thinning over the past two years, primarily at the crown and along the frontal hairline. He describes a slowly receding hairline and a small bald spot that has become more noticeable over time. He denies any itching, redness, or flaking, and there are no visible signs of inflammation or scarring on the scalp. His family history is positive for male pattern baldness on both his paternal and maternal sides. He has no significant medical conditions aside from seasonal allergies and takes loratadine and a daily multivitamin.
Epidemiology
Studies estimate that approximately 30% to 50% of men will exhibit signs of MAA by the age of 50.1 In general, Caucasian men are more likely to develop earlier and more severe forms of AGA compared to men of Asian or African-American descent.1 There is also a strong correlation between age and MAA.1 In a cohort study of Australian men aged 40–69 years, the prevalence of vertex or full baldness rose from 31% among those aged 40–55 to 53% in those between the ages of 65 and 69.1 In the United States, a survey found that 53% of men aged 40–49 had moderate to severe AGA.¹ While AGA most commonly affects men, it is a genetically driven condition that can affect women as well.3
Etiology
Androgenetic alopecia is a multifactorial condition that results from genetic predisposition and androgenic activity.4 It is the most common form of nonscarring alopecia and is characterized by a progressive miniaturization of hair follicles in androgen-sensitive regions of the scalp.4
Genetic Contributions
Family history is one of the strongest predictors of AGA.1 Epidemiological studies have shown a clear familial tendency, with hair loss patterns often resembling those of close relatives.1 Notably, while some resemblance exists between fathers and sons, studies have demonstrated a stronger association between affected males and their maternal grandfathers, implicating the androgen receptor (AR) gene on the X chromosome.1 This gene modulates the follicular response to dihydrotestosterone (DHT), but the attributable risk from this single locus is limited.1 This suggests that additional autosomal genes contribute to the phenotype.1 Recent evidence supports a polygenic model, where multiple gene variants together increase the risk of developing AGA.1
Hormonal and Follicular Mechanisms
Androgenetic alopecia is an androgen-dependent condition, and hair loss does not occur in individuals with androgen insensitivity.3 The AR gene polymorphism may explain differential follicular sensitivity to DHT in balding versus non-balding scalp regions.3 Interestingly, serum androgen levels in affected individuals are typically within normal limits, which suggests that emphasizing that local follicular metabolism, rather than systemic hormone levels, is causative.3 The degree of follicular sensitivity to androgens appears to be genetically determined.3 Individuals with a strong genetic predisposition may begin losing hair in their late teens, while those with a weaker predisposition may not show signs until late adulthood.3
Causes of Hair Loss
Hair loss can result from numerous underlying causes, and accurate identification of the etiology is essential for effective management.4 Physiological stressors—including infections, fever, trauma, and recent surgeries—can lead to temporary hair shedding.4 Chronic illnesses such as autoimmune disorders, thyroid abnormalities, diabetes, hepatic or renal failure, and infections like HIV or syphilis can also disrupt the hair cycle.4 Numerous medications have also been found to cause hair loss, including chemotherapeutic agents, anticoagulants, antidepressants, and beta blockers.4 Additionally, dietary factors, such as rapid weight loss, protein deficiency, or inadequate intake of key nutrients like iron, zinc, or biotin, can contribute to hair thinning.4
Primary care providers, pharmacists, dermatologists, and nutritionists all play critical roles in evaluating and managing hair loss. Providers should conduct a thorough medical history and medication review, identify reversible factors, and provide education on proper hair care, nutrition, and treatment options. Pharmacists are particularly well-positioned to identify medication-related causes and recommend alternatives or supportive therapies, while dietitians can address nutritional deficiencies contributing to alopecia. Collaborative, patient-centered care ensures accurate diagnosis and tailored interventions that improve both clinical outcomes and patient quality of life. The various causes of hair loss are summarized in Table 1, with examples provided.3
Table 1
Causes of Hair Loss
| Category | Specific Examples |
|---|---|
Hormonal changes
| Hyperandrogenic conditions (e.g., polycystic ovary syndrome) |
| Menopause | |
| Postpartum period | |
Physiologic stress
| Fever, infections |
| Hemorrhage | |
| Surgery | |
| Trauma | |
Chronic illnesses
| Autoimmune diseases (e.g., rheumatoid arthritis, lupus) |
| Eating disorders (e.g., anorexia, bulimia) | |
| Endocrine disorders (e.g., hypothyroidism/hyperthyroidism, hypopituitarism, diabetes mellitus, metabolic syndrome, hyperprolactinemia) | |
| Hepatic or renal failure | |
| Infections (e.g., HIV infection, syphilis) | |
Medications
| ACE inhibitors (e.g., enalapril, captopril) |
| Allopurinol | |
| Androgenic action (e.g., oral contraceptives, danazol, testosterone, anabolic steroids) | |
| Anticonvulsants (e.g., phenytoin, carbamazepine, valproate) | |
| Anticoagulants (e.g., warfarin, heparin) | |
| Antidepressants (e.g., SSRIs, tricyclic antidepressants) | |
| Beta blockers (e.g., propranolol, metoprolol) | |
| Cholesterol-lowering drugs (e.g., clofibrate, gemfibrozil) | |
| Chemotherapeutic agents | |
Dietary changes or deficiencies
| Protein restriction/deficiency |
| Rapid weight loss, including that associated with bariatric surgery | |
| Strict vegetarian diet | |
| Zinc, biotin, or iron deficiency | |
Local trauma
| Hair care practices |
| Tinea capitis | |
| Trichotillomania (compulsive hair plucking) |
Pathophysiology
Hair growth occurs in a cyclical process involving the anagen (growth), catagen (regression), and telogen (resting) phases.4 In AGA, this cycle is disrupted.4 The anagen phase becomes progressively shorter, while the telogen phase lengthens, resulting in decreased hair density and increased shedding.4 Affected hair follicles undergo miniaturization—a process in which terminal hairs are replaced by vellus-like hairs that are shorter, finer, and less pigmented.4 Over time, follicular activity may cease altogether, leading to visible baldness.4 From a histological perspective, perifollicular inflammation, increased collagen deposition, and fibrosis in the dermal sheath can be seen.4
The enzyme 5α-reductase plays a critical role in converting testosterone into DHT.3,4 Type II 5α-reductase is predominantly active in the scalp and prostate.3,4 Dihydrotestosterone binds to androgen receptors with greater affinity than testosterone, promoting gene transcription that leads to follicular regression. In men with AGA, affected follicles show increased levels of 5α-reductase and androgen receptors.3,4 Emerging evidence also suggests that oxidative stress and microinflammation may cause follicular miniaturization, and inflammatory changes may accelerate follicular involution and reduce treatment responsiveness.3,4
Diagnosis
The diagnosis of AGA is primarily clinical and based on the pattern of hair loss.3,4 Key features include:
Gradual onset of thinning, typically beginning at the temples or crown
Preservation of the occipital scalp and lateral margins
Absence of scalp erythema or scaling
Positive family history
Staging Male Pattern Baldness
The Norwood-Hamilton classification is used to stage male pattern baldness, ranging from stage I (minimal recession) to stage VII (extensive hair loss with only a horseshoe-shaped fringe remaining).3 Dermoscopy may reveal miniaturized hairs and yellow dots, further supporting the diagnosis.3
In cases where the diagnosis is uncertain, additional workup may include the following.3
Hair pull test: more than 10% of hairs removed suggests active shedding
Trichoscopy: identifies characteristic features such as vellus hairs and peripilar signs
Laboratory testing: recommended if there are signs of systemic illness, rapid onset, or scarring
Differential Diagnosis
Differential diagnoses to consider include telogen effluvium, a reactive process characterized by diffuse hair shedding; alopecia areata, an autoimmune disorder resulting in patchy hair loss; tinea capitis, a fungal infection commonly found in children; and trichotillomania, a compulsive hair-pulling behavior.3 These conditions may overlap in presentation, particularly in early stages, and thus require careful assessment. Referral to a dermatologist is strongly recommended in cases of diagnostic uncertainty, non-classical hair loss patterns, or when scarring alopecia is suspected.3 Dermatologists can perform specialized diagnostic procedures such as dermoscopy, scalp biopsies, and fungal cultures to distinguish between similar-appearing conditions and guide targeted treatment. In all cases, collaborative care among healthcare professionals ensures a patient-centered, accurate, and efficient approach to diagnosing and managing hair loss.
Management Strategies
Effective management of AGA requires a personalized, patient-centered approach that balances clinical efficacy with safety and patient preferences.3 While current therapies aim to slow progression and promote regrowth, no cure exists, and adherence to long-term treatment is critical for success.3 For many men, addressing hair loss also reduces the psychological distress and self-esteem challenges that may accompany visible thinning. The treatment approach should be individualized based on the cause, severity, location of hair loss, patient preference, and tolerability of available therapies.3
Nonpharmacologic Strategies
Nonpharmacologic interventions play an important role in the management of AGA and can be used alone or alongside pharmacologic options.4 Cosmetic techniques, such as the use of wigs, hairpieces, colored scalp fibers, and topical sprays, can help mask thinning hair and offer immediate aesthetic improvements even though they do not prevent further hair loss.4 Other interventions include low-level laser therapy (LLLT) devices, such as combs or helmets, which are FDA-cleared for AGA and may stimulate follicular activity through improved microcirculation.4 Microneedling has also shown promise in improving minoxidil efficacy and increasing hair density.4 In certain patients, hair transplantation, which is the process of surgically relocating follicles from the occipital scalp to thinning areas, may be an option.4 For patients with dietary deficiencies or iron-deficiency anemia, correction of underlying nutritional issues through diet or supplementation may help promote regrowth.4
Topical Pharmacotherapy
Topical minoxidil is the first-line pharmacologic treatment for AGA and remains the only FDA-approved OTC medication for this condition.4 Minoxidil is available as a 2% or 5% hydroalcoholic solution and a 5% propylene glycol–free foam.5 It works by prolonging the anagen (growth) phase of the hair cycle, increasing follicular size, promoting vascular endothelial growth factor release, and may also exert local antiandrogenic effects.5 For men, the 5% solution or foam is typically recommended and applied twice daily to the affected scalp.4 The foam formulation is often preferred in individuals with sensitive skin, as it lacks propylene glycol, a common irritant that can lead to contact dermatitis.4 Minoxidil dosing, use, and patient counselling are covered in Tables 2 and 3.
Table 2
Minoxidil Treatment
| Medication | Formulation | Dose | Mechanism of Action | Common Side Effects |
|---|---|---|---|---|
| Minoxidil | 2% or 5% solution; 5% foam | Men: 1 mL twice daily; Foam: half-capful twice daily | Vasodilator, prolongs the anagen phase, enhances VEGF expression | Scalp irritation, itching, hypertrichosis |
Table 3
Minoxidil Use and Counseling
| Topic | Counseling Point |
|---|---|
| Application Site | Apply to clean, dry scalp, not hair. |
| Dosage | Use 1 mL of solution or ½ capful of foam per application. |
| Frequency | Men: twice daily; Women (foam): once daily. |
| Administration Tips | Gently massage into scalp with fingertips; wash hands after. |
| Missed Dose | Do not double the next dose; resume your regular schedule. |
| Drying Time | Allow 2–4 hours before swimming, showering, or lying down. |
| Bedtime Use | Apply 2–4 hours before bed to prevent staining linens. |
| Hair Products | Apply styling products only after minoxidil dries. |
| Hair Treatments | Avoid minoxidil use 24 hours before and after coloring or chemical treatments. |
| Foam-Specific Advice | Use cool, dry hands for application; foam may melt on warm skin. |
| Foam Technique | Part hair, apply foam to scalp (not hair), then gently massage in. |
Minoxidil must be used continuously to maintain its effects, as discontinuation typically results in hair returning to baseline within several months.3,4 Hair regrowth may take 4 to 6 months to become noticeable.2,3 Early in treatment, transient shedding may occur due to telogen hairs entering the anagen phase, and patients should be reassured that this is a normal and temporary phase.3 Adverse effects are typically mild and localized, including itching, irritation, dryness, or scaling.5 Hypertrichosis, particularly on the forehead or cheeks, may occur with excessive use or incorrect application.5 Systemic side effects are rare but may include dizziness, chest pain, or tachycardia, particularly in patients with underlying cardiovascular conditions.5
Efficacy studies have demonstrated that the 5% solution yields significantly greater regrowth than the 2% formulation, with some studies reporting up to 45% more new hair at the vertex scalp after 48 weeks.6 Despite its benefits, approximately 60% of male patients do not respond to minoxidil.3 This variability may be related to differences in follicular sulfotransferase enzyme activity, which converts minoxidil to its active form.3 Minoxidil may be used in combination with oral finasteride, a prescription 5α-reductase inhibitor, to enhance outcomes. Studies suggest that combination therapy produces better results than either treatment alone.3 Minoxidil also supports outcomes following hair transplantation by improving graft survival and minimizing the progression of non-transplanted hair loss.3
Systemic Therapies
Finasteride, an oral 5α-reductase inhibitor, is approved for AGA at a daily dose of 1 mg and works by inhibiting the conversion of testosterone to dihydrotestosterone.7 Clinical trials have shown significant increases in hair count and thickness within 6 to 12 months of therapy, with benefits sustained through continued use.3 However, discontinuation typically results in hair returning to pretreatment levels, sometimes more rapidly than baseline progression.3 Adverse effects include decreased libido, erectile dysfunction, and, more rarely, gynecomastia or mood changes.3,7 Monitoring liver function during long-term use is recommended due to its hepatic metabolism.3,7
Dutasteride is a second-generation 5α-reductase inhibitor that blocks both type I and type II enzymes, and it has demonstrated superior DHT suppression and greater efficacy in some studies compared with finasteride.3,8 However, it is not FDA-approved for AGA in the United States, though it is used off-label and is approved in other countries.3 Due to its longer half-life and stronger enzyme inhibition, adverse effects may persist longer after discontinuation.3
The use of finasteride and dutasteride is covered in Table 4.
Table 4
5α-reductase Inhibitors
| Medication | Class | Dose | Mechanism of Action | Common Side Effects |
|---|---|---|---|---|
| Finasteride | Type II 5α-reductase inhibitor | 1 mg daily | Inhibits DHT formation | Decreased libido, erectile dysfunction, gynecomastia |
| Dutasteride | Dual 5α-reductase inhibitor | 0.5 mg daily (off-label) | Inhibits type I and II 5α-reductase | Similar to finasteride; longer half-life |
Complementary and Herbal Therapies
Complementary and alternative therapies are widely marketed, though data supporting their use vary in quality.4 A recent systematic review of nutritional supplements identified several formulations with potential benefit and low risk of harm, including Viviscal, Nutrafol, omega-3/6 fatty acids with antioxidants, zinc, pumpkin seed oil, and proprietary blends such as Lambdapil.9 While these products should not replace evidence-based medical therapy, they may be useful as adjuncts or in patients who decline pharmacologic treatment.4 Patient counseling should emphasize realistic expectations and the need for consistent, long-term use.4
Surgical Approaches
Hair transplantation remains a definitive treatment for men with extensive, stable AGA. Two main techniques are utilized.3
Follicular Unit Transplantation (FUT): Strip harvesting
Follicular Unit Extraction (FUE): Individual follicle harvesting
Both approaches require healthy donor areas and may be complemented by medical therapies to preserve surrounding hair.
Psychosocial Impact and Stigma
Hair plays a powerful role in personal identity, cultural expression, and social perception.2 Men with AGA often experience emotional distress, diminished confidence, and impaired interpersonal relationships.3 Studies link AGA with increased rates of depression and anxiety, particularly in younger men. Social stigma is exacerbated by cultural ideals equating hair with masculinity and attractiveness. Moreover, racial and gender biases influence patient experiences. Black men and those with tightly coiled hair may feel misunderstood in clinical settings where hair types are poorly represented in educational materials and research.3
Clinicians should approach AGA holistically, recognizing the emotional and cultural dimensions of hair loss. Key considerations include:
Normalizing the condition without minimizing its impact
Offering empathetic communication and shared decision-making
Referring to counseling or support groups when needed
Being sensitive to diverse hair textures and cultural practices
Patient Case
Given the absence of inflammation, scarring, or secondary causes, and a strong family history of male pattern baldness, he was diagnosed with androgenetic alopecia. First-line treatment includes initiating topical minoxidil 5% foam or solution twice daily to the affected areas to promote hair regrowth and slow progression. After discussing risks and benefits, oral finasteride 1 mg daily was also recommended. MR was counseled on the importance of consistent, long-term adherence to therapy, with an expectation of visible improvement within 3 to 6 months. A follow-up in 6 months was scheduled to assess treatment response and tolerability.
Summary
Male pattern baldness, or AGA, is a highly prevalent condition that can significantly affect quality of life. While not medically harmful, its psychosocial impact is substantial, often prompting patients to seek treatment. Androgenetic alopecia is the only type of alopecia with FDA-approved over-the-counter pharmacologic therapy—topical minoxidil—making it an accessible first-line option. When appropriate, prescription oral therapies, such as finasteride or off-label dutasteride, may be used, particularly for patients who do not respond adequately to topical agents. Nonpharmacologic approaches, including LLLT, cosmetic camouflage, nutritional optimization, and hair transplantation, provide additional avenues for personalized care. Clinicians should guide patients through the broad array of therapeutic options, set realistic expectations regarding efficacy and maintenance, and monitor treatment adherence and adverse effects. With a patient-centered, evidence-based approach, healthcare professionals can help men experiencing AGA achieve improved cosmetic outcomes and psychological well-being.
References
Asfour L, Cranwell W, Sinclair R. Male androgenetic alopecia. In: Endotext. Updated January 25, 2023. Accessed June 17, 2025. https://www.ncbi.nlm.nih.gov/books/NBK278957/
Hordinsky MK. Hair Disorders. In: Soutor C, Hordinsky MK. eds. Clinical Dermatology: Diagnosis and Management of Common Disorders, 2e. McGraw-Hill Education; 2022.
Law RM, Do LD, Maibach HI. Alopecia. In: DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey L, eds. DiPiro’s Pharmacotherapy: A Pathophysiologic Approach. 12th ed. McGraw Hill; 2023.
Berry TM. Hair loss. In: APhA OTC - Dermatologic Disorders. Nonprescription Product Therapeutics. Ch. Hair Loss. APhA. Published 2024.
Rogaine® (minoxidil 5%) foam [package insert]. Johnson & Johnson Consumer Inc.; revised December 2022.
Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–385. doi:10.1067/mjd.2002.124088
Propecia® (finasteride 1 mg) tablets [package insert]. Organon LLC; revised February 2023. Accessed June 17, 2025.
Avodart® (dutasteride 0.5 mg) capsules [package insert]. GlaxoSmithKline; revised October 2023.
Drake L, Reyes-Hadsall S, Martinez J, Heinrich C, Huang K, Mostaghimi A. Evaluation of the safety and effectiveness of nutritional supplements for treating hair loss: a systematic review. JAMA Dermatol. 2023;159(1):79-86. doi:10.1001/jamadermatol.2022.4867
DISCLAIMER
The information provided in this course is general in nature, and it is designed solely to provide participants with continuing education credit(s). This course and materials are not meant to substitute for the independent, professional judgment of any participant regarding that participant’s professional practice, including but not limited to patient assessment, diagnosis, treatment, and/or health management. Medical and pharmacy practices, rules, and laws vary from state to state, and this course does not cover the laws of each state; therefore, participants must consult the laws of their state as they relate to their professional practice.
Healthcare professionals must consult their employer, healthcare facility, hospital, or other organization for guidelines, protocols, and procedures to follow. The information provided in this course does not replace those guidelines, protocols, and procedures, but is for academic purposes only, and this course’s limited purpose is for the completion of continuing education credits.
Participants are advised and acknowledge that information related to medications, their administration, dosing, contraindications, adverse reactions, interactions, warnings, precautions, or accepted uses is constantly changing. Any person taking this course understands that such a person must make an independent review of medication information before any patient assessment, diagnosis, treatment and/or health management. Any discussion of off-label use of any medication, device, or procedure is informational only, and such uses are not endorsed hereby.
Nothing contained in this course represents the opinions, views, judgments, or conclusions of RxCe.com LLC. RxCe.com LLC is not liable or responsible to any person for any inaccuracy, error, or omission with respect to this course or course material.
© RxCe.com LLC 2026: All rights reserved. No reproduction of all or part of any content herein is allowed without the prior, written permission of RxCe.com LLC.
RxCe.com
© RxCe.com LLC 2025: All rights reserved.